PMID- 25678238
OWN - NLM
STAT- MEDLINE
DCOM- 20160404
LR  - 20200923
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 30
IP  - 7
DP  - 2015 Jul
TI  - Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
PG  - 1116-22
LID - 10.1111/jgh.12916 [doi]
AB  - Advanced cholangiocarcinoma (CCA) is a highly lethal disease with limited 
      therapeutic options beyond cytotoxic chemotherapy. Molecular profiling of CCA has 
      provided insights into the pathogenesis of this disease and identified potential 
      therapeutic targets. The fibroblast growth factor receptor (FGFR) axis is 
      important for maintaining tissue homeostasis. Aberrations in FGFR activity have 
      been implicated in the development and progression of CCA and other malignancies, 
      which has generated significant interest in exploring FGFR's therapeutic 
      potential. FGFR2 fusion events are present in up to 17% of intrahepatic CCAs and 
      appear to predict sensitivity to FGFR inhibitors even after progression on 
      chemotherapy. These observations have led to a clinical trial evaluating FGFR 
      inhibition in patients with CCA enriched for FGFR alterations. This review 
      summarizes current knowledge about the role of the FGFR pathway in 
      cholangiocarcinogenesis and ongoing work in developing FGFR-directed therapies as 
      an antineoplastic strategy for CCA.
CI  - (c) 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing 
      Asia Pty Ltd.
FAU - Ang, Celina
AU  - Ang C
AD  - Division of Medicine, Hematology, and Medical Oncology, Mount Sinai School of 
      Medicine, New York, New York, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Receptors, Fibroblast Growth Factor)
RN  - 0 (Triazines)
RN  - A4055ME1VK (infigratinib)
RN  - DDU33B674I (brivanib)
RN  - EC 2.7.10.1 (FGFR2 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 2)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Alanine/analogs & derivatives
MH  - Antineoplastic Agents
MH  - Bile Duct Neoplasms/drug therapy/*genetics
MH  - Cholangiocarcinoma/drug therapy/*genetics
MH  - Chromosome Aberrations
MH  - Drug Discovery
MH  - Gene Fusion
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Phenylurea Compounds
MH  - Protein Kinase Inhibitors
MH  - Pyrimidines
MH  - Receptor, Fibroblast Growth Factor, Type 2/genetics
MH  - Receptors, Fibroblast Growth Factor/antagonists & 
      inhibitors/*genetics/*physiology
MH  - Signal Transduction/genetics/physiology
MH  - Triazines
OTO - NOTNLM
OT  - cholangiocarcinoma
OT  - fibroblast growth factor receptor
OT  - tyrosine kinase inhibitor
EDAT- 2015/02/14 06:00
MHDA- 2016/04/05 06:00
CRDT- 2015/02/14 06:00
PHST- 2015/01/22 00:00 [accepted]
PHST- 2015/02/14 06:00 [entrez]
PHST- 2015/02/14 06:00 [pubmed]
PHST- 2016/04/05 06:00 [medline]
AID - 10.1111/jgh.12916 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2015 Jul;30(7):1116-22. doi: 10.1111/jgh.12916.